Last edition
News about Drug Discovery & Development
Daiichi Sankyo's quizartinib plus chemotherapy improves OS in patients with AML
Quizartinib combined with standard induction and consolidation chemotherapy and then continued as a single agent demonstrated a 22.4 per cent reduction in the risk of death
Drug Discovery & Development | 13/06/2022 | By Sudeep Soparkar | 829
Autoimmune drug by Bristol Myers shows potential in lupus
Deucravacitinib is one of nine new drugs that Bristol Myers executives believe will help offset revenue losses
Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar | 785
PerkinElmer unveils ultrarapid whole-genome sequencing
The urWGS offering provides physicians with comprehensive, meaningful results in five days to help inform clinical management and improve outcomes
Drug Discovery & Development | 08/06/2022 | By Sudeep Soparkar | 529
BioNTech 2nd phase of Covid 19 trials completed
The vaccine, based on messenger RNA (mRNA) technology, is one of the most widely used worldwide against COVID, but has yet to receive an approval in China, which has relied only on domestically-developed vaccine
Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar | 673
US FDA approval for Incyte's Olumiant
Eli Lilly and Company and Incyte announced the US Food and Drug Administration (FDA) has approved Olumiant (baricitinib) for the treatment of Covid-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days.
Drug Discovery & Development | 12/05/2022 | By Sudeep Soparkar | 783
The Dutch company MIMETAS expanded its license to the HUB Organoid Technology to include all organs
These miniature organs are used to develop therapies against incurable diseases.
Drug Discovery & Development | 11/05/2022 | By Content editor | 1031
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy